You have free access to this content

Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings

  1. John S Freiman,
  2. Geoffrey W M C

Article first published online: 25 DEC 2001

DOI: 10.1046/j.1440-1746.2000.02129.x

Issue

Journal of Gastroenterology and Hepatology

Journal of Gastroenterology and Hepatology

Volume 15, Issue 3, pages 227–229, March 2000

Additional Information

How to Cite

Freiman, J. S. and M, G. W. (2000), Current limitations to nucleoside analogue therapy for chronic hepatitis B virus infection in the liver transplant and non-transplant settings. Journal of Gastroenterology and Hepatology, 15: 227–229. doi: 10.1046/j.1440-1746.2000.02129.x

Author Information

  1. Department of Gastroenterology, St George Hospital, Kogarah and

* Correspondence: ProfessorGMcCaughan AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown NSW 2050, Australia. Email: g.mccaughan@centenary. usyd.edu.au

Publication History

  1. Issue published online: 25 DEC 2001
  2. Article first published online: 25 DEC 2001

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (44K)

REFERENCES

  • 1
    Luscombe C & Locarnini S. The mechanism of action of antiviral agents in chronic hepatitis B. Viral Hepatitis Reviews 1996; 2: 1 35.
  • 2
    Main J, Brown J, Howells C, Galassini R, Crossey M, Karayiannis P. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Viral Hepatitis 1996; 3: 211 15.
    Direct Link:
  • 3
    Dienstag JL, Perillo RPI, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 1657 61.
  • 4
    Lai CL, Chien RN, Leung NWY et al. One year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 61 7.
  • 5
    Todo S, Demetris AJ, Van Thiel D, Teperman L, Fun JJ, Stazl TE. Orthotopic liver transplanation for patients with hepatitis B virus-related disease. Hepatology 1991; 13: 619 26.
  • 6
    Devlin J, Smith HM, Drotman B, Tan KC, Williams R. Impact of immunoprophylaxis and patient selection on outcome of transplantation for HBsAg positive liver recipients. J. Hepatol. 1994; 21: 204 10.
  • 7
    Samuel D, Bismuth A, Matthieu D et al. Passive immunoprophylaxis after liver transplantation in HBsAg positive patients. Lancet 1991: 337: 813 15.
  • 8
    Terrault NA, Zhou S, Combes C et al. Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin. Hepatology 1996; 24: 1327 33.
    Direct Link:
  • 9
    Angus P, Locarnini S, McCaughan GW, June R, Bowden S. Hepatitis B virus precore mutant infection is associated with severe recurrent disease following liver transplanatation. Hepatology 1995; 21: 14 18.
    Direct Link:
  • 10
    Nauman U, Protzer-Knolle U, Berg T et al. A pre-transplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti hepatitis B virus surface antigen immunoprophylaxis. Hepatology 1997; 26: 478 84.
    Direct Link:
  • 11
    McGory R, Ishitani M, Oliveira W et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunisation. Transplantation 1996; 61: 1358 64.
  • 12
    Adler R, Safadi R, Carco Y et al. Comparision of immune reactivity and pharmacokinetics of two hepatitis B immune globulins in patients after liver transplantation. Hepatology 1999; 29: 1299 1305.
    Direct Link:
  • 13
    Grellier L, Mutimer D, Ahmed M et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212 15.
  • 14
    Markowitz JS, Martin P, Conrad AJ et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin Hepatology 1998; 28: 585 9.
    Direct Link:
  • 15
    McCaughan GW, Spencer J, Koorey D et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant associated infection. High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transplant Surg. 1999; 5: 512 19.
    Direct Link:
  • 16
    McCaughan GW, Koorey D, Spencer J et al. Prophylactic lamivudine and very low dose HBIG prevent HBV recurrence post liver transplant whilst rescue therapy with lamivudine is associated with significant resistance and graft loss. Hepatology 1998; 28: 263A.
  • 17
    Perrillo R, Jorge R, Dienstag J et al. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Hepatology 1999; 29: 1581 6.
    Direct Link:
  • 18
    Ling R, Mutimer D, Ahmed M, Boxall E, Elias E, Dusheiko G. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24: 711 13.
    Direct Link:
  • 19
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kreteman NM, Tyrell DLJ. Mutation in HBV RNA-dependant DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24: 714 17.
  • 20
    Allen MI, Deslauriers M, Andrews CW et al. Identification and characterisation of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670 7.
    Direct Link:
  • 21
    Leung NWY, Lai CL, Change TT et al. Three year lamivudine therapy in chronic HBV. J Hepatol. 1999; 30 (Suppl.): 59 (Abstract).
  • 22
    Boni T, Bertoletti A, Penna A et al. Lamivudine treatment can restore T-cell responsiveness in chronic hepatitis B. J. Clin. Invest. 1998; 102: 968 75.
  • 23
    Colledge D, Locarnini S, Shaw T. Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 1997; 26: 216 25.
  • 24
    Bartholomeusz A, Groenen LC, Locarnini SA. Clinical experience with famciclovir against hepatitis B virus. Intervirology 1997; 40: 337 42.
  • 25
    Nicoll A, Locarnini S, Chou ST, Smallwood R, Angus P. Effect of nucleoside analogue therapy on duck hepatitis B viral replication in hepatocytes and bile duct epithelial cells in vivo. J. Gastroenterol. Hepatol. 2000; 15: 304 10.
    Direct Link:
  • 26
    Freiman JS, Jilbert AR, Dixon RJ et al. Experimental duck hepatitis B virus infection: Pathology and evolution of hepatic and extrahepatic infection. Hepatology 1988; 8: 507 13.
    Direct Link:
View Full Article (HTML) Get PDF (44K)